AP

Change at the top for Biogen after Alzheimer’s drug flops

May 3, 2022, 4:39 AM | Updated: 10:57 am

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers.

CEO Michel Vounatsos will continue to lead the Biogen until a successor is found, the company announced Tuesday. Vounatsos joined the company in 2016 and was the chief architect of Biogen’s strategy built around Aduhelm.

For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company’s flagging biotech business.

The announcement represents a stark acknowledgement that the Cambridge, Massachusetts-based company has failed to find a market for a drug that was expected to drive its business for years to come.

Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster drug that would generate billions for Biogen.

But doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage over the drug’s high price tag and uncertain benefit. Even the company’s decision to slash the drug’s price in half– to $28,000 a year — did little to improve uptake.

The biggest setback came last month when the federal government’s Medicare health plan imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. The vast majority of U.S. Alzheimer’s patients are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older.

The infused drug brought in just $2.8 million in sales in the first quarter, which ended March 31.

Biogen said Tuesday that it booked about $275 million in charges from Aduhelm inventory write-offs in the quarter, and it would essentially shutdown its sales and marketing infrastructure supporting the drug.

Aduhelm expenses dragged down the company’s quarterly results and Biogen fell short of Wall Street projections, reporting adjusted net income of $535 million, or $3.62 per share. Analysts forecast earnings of $4.34 per share, according to FactSet.

Biogen executives said the restrictive Medicare decision essentially denied Aduhelm to most eligible U.S. patients. Last month the company announced it was pulling its marketing application for the drug in Europe.

Biogen will continue running a federally-mandated confirmatory trial designed to establish if the drug truly slows Alzheimer’s.

The drugmaker’s quarterly revenue fell 6% to $2.5 billion, pressured by lower sales of multiple sclerosis drugs in the U.S. due to cheaper, generic competition. The company also reported lower sales of its specialty drug Spinraza, which is used to treat a rare spinal disorder in children.

For the year, Biogen reaffirmed earnings guidance of between $14.25 and $16.00 per share.

Biogen executives said they will continue pursuing new Alzheimer’s treatments including a drug similar to Aduhelm. Researchers are awaiting last-stage testing results for the drug in the fall. But the company also highlighted other drugs in its pipeline, including potential treatments for depression and schizophrenia.

Vounatsos departure was expected “given the many setbacks the company has faced,” RBC Capital Markets analyst Brian Abrahams wrote Tuesday. The move and reorganization “will be well received over the long term, and give the company a fresh start in refocusing R&D priorities.”

Shares of Biogen Inc. rose less than 1%.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Republican presidential candidates, from left, former Arkansas Gov. Asa Hutchinson, former New Jers...

Associated Press

3rd Republican presidential debate is set for Nov. 8 in Miami, with the strictest qualifications yet

The third Republican presidential debate will be held in Miami on Nov. 8, a day after several states hold off-year elections.

2 days ago

During the equinox, the Earth’s axis and its orbit line up so that both hemispheres get an equal ...

Associated Press

The fall equinox is here. What does that mean?

The equinox arrives on Saturday, marking the start of the fall season for the Northern Hemisphere. But what does that actually mean?

2 days ago

Ray Epps Ray Epps, an Arizona man who became the center of a conspiracy theory about Jan. 6, 2021, ...

Associated Press

Ray Epps, an Arizona man who supported Trump, pleads guilty to Capital riot charge

Ray Epps, the target of a conspiracy theory about the Jan. 6, 2021, attack, pleaded guilty on Wednesday to a misdemeanor charge.

4 days ago

Former President Donald Trump repeatedly declined in an interview aired Sunday, Sept. 17, 2023, to ...

Associated Press

Trump refuses to say in a TV interview how he watched the Jan. 6 attack unfold at the US Capitol

Former President Donald Trump repeatedly declined in an interview aired Sunday to answer questions about whether he watched the Capitol riot.

7 days ago

This frame grab from video, provided by the Mexican government, shows Ovidio Guzman Lopez being det...

Associated Press

Mexico extradites son of ‘El Chapo,’ Ovidio Guzman Lopez to US

The son of notorious cartel leader Joaquin “El Chapo” Guzmán, Ovidio Guzman Lopez was extradited to the U.S. on Friday.

8 days ago

impeachments in US history...

Associated Press

A look at notable impeachments in US history, including Texas Attorney General Ken Paxton

Texas Attorney General Ken Paxton was acquitted Saturday on during his impeachment trial. Here's a roundup of impeachments in U.S. history.

8 days ago

Sponsored Articles

Home moving relocation in Arizona 2023...

BMS Moving

Tips for making your move in Arizona easier

If you're moving to a new home in Arizona, use this to-do list to alleviate some stress and ensure a smoother transition to your new home.

...

Ignite Digital

How to unlock the power of digital marketing for Phoenix businesses

All businesses around the Valley hopes to maximize their ROI with current customers and secure a greater market share in the digital sphere.

...

re:vitalize

When most diets fail, re:vitalize makes a difference that shows

Staying healthy and losing weight are things many people in Arizona are conscious of, especially during the summer.

Change at the top for Biogen after Alzheimer’s drug flops